Free Republic

KEY POINTS * Johnson & Johnson's vaccine won't capture nearly as much market share as Pfizer and Moderna this year. * The company's vaccine has been at a disadvantage due to a perceived lower efficacy rate. * Its effectiveness against the delta variant could lead to an increase in demand. Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccine has had some challenges this year. From production issues to some disquieting reports of blood clots possibly being linked to the vaccine, it hasn't been the success the company was likely hoping it would be at this stage. Vaccines from Pfizer (NYSE:PFE) and Moderna...

<p>At one point, Johnson & Johnson (NYSE: JNJ) seemed to have a pretty good shot at becoming the leader in the COVID-19 vaccine market. Unlike rival vaccines, J&J's vaccine required only a single dose. The company even committed to selling its vaccine at cost during the pandemic, giving it a big price advantage compared to the vaccines developed by Pfizer and Moderna.</p>

CHICAGO—Scientists at Johnson & Johnson on Friday refuted an assertion in a major medical journal that the design of their COVID-19 vaccine, which is similar AstraZeneca’s, may explain why both have been linked to very rare brain blood clots in some vaccine recipients. The United States earlier this week paused distribution of the J&J vaccine to investigate six cases of a rare brain blood clot known as cerebral venous sinus thrombosis (CVST), accompanied by a low blood platelet count, in U.S. women under age 50, out of about 7 million people who got the shot. The blood clots in patients...

As concerns mount over the efficacy of the Johnson & Johnson one-shot vaccine, the Bay Area’s leading public health officials have come together for what appears to be their definitive statement on the vaccine options currently available in the United States. Public health officers from Santa Cruz, Berkeley and all nine Bay Area counties — Alameda, Contra Costa, Marin, Napa, San Francisco, San Mateo, Santa Clara, Solano and Sonoma — issued a statement Monday emphasizing the fact that all of the vaccine options are “safe and have been shown to be highly effective at preventing symptomatic illness and hospitalization.” “The...

The World Health Organization (WHO) on Friday granted emergency use listing to a single-dose coronavirus vaccine developed by Johnson & Johnson, marking the fourth jab cleared to rollout among developing countries through a global initiative called COVAX. The WHO will convene an advisory group of experts next week to form recommendations for use of the vaccine, Dr. Tedros Adhanom Ghebreyesus, WHO director-general, said during a briefing Friday. "We hope that this new vaccine will help to narrow vaccine inequalities and not deepen them," Tedros said. He added that the COVAX facility booked 500 million doses of the single-shot vaccine, and...

<p>Johnson & Johnson jab becomes the fourth inoculation to receive green light in EU.</p><p>The European Medicines Agency (EMA) on Thursday approved the COVID-19 coronavirus vaccine developed and produced by Johnson & Johnson.</p><p>The vaccine became the fourth jab to get the green light from the 27-nation bloc.</p>